New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients

Recruiting now · Not applicable

Conditions studied: Chronic Kidney Disease

In brief

To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.

Key facts

Study ID

NCT02808572

Run by

University Hospital, Montpellier

People needed

250

Starts

2013-03-12

Expected to finish

2031-06-01

Last updated by the study team

2022-01-04

Who can join

Age: 18 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient who has signed the written consent form
• Patient with chronic renal failure defined by glomerular filtration rate (GFR) but without dialysis therapy

You may not qualify if…

• Pregnancy
• Patient with chronic renal failure requiring dialysis therapy

Where it is running

• CHU Montpellier, Endocrinology department — Montpellier, France (enrolling)
• CHU Montpellier, Nephrology department — Montpellier, France (enrolling)
• AIDER — Montpellier, France (enrolling)
• AIDER — Saint-Jean-de-Védas, France
• CHU Montpellier, Intensive care unit — Montpellier, France
• CHU Montpellier, Cardiology department — Montpellier, France
• CHU Montpellier, Internal medicine department — Montpellier, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.